-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Maintains Overweight on Repligen, Lowers Price Target to $190

Benzinga·04/29/2025 22:00:02
Listen to the news
JP Morgan analyst Rachel Vatnsdal maintains Repligen (NASDAQ:RGEN) with a Overweight and lowers the price target from $200 to $190.